B-Cell CD40 Expression by Flow Cytometry, Blood
The CD40–CD40 ligand (CD40L) interaction plays a central role in both humoral and cellular immune responses. CD40 is a costimulatory receptor highly expressed on B-cells, dendritic cells, macrophages, and other antigen-presenting cells. Upon antigen recognition, activated T helper cells express CD40L (CD154), which binds to CD40 on B-cells, initiating an intracellular signaling cascade through TRAF adapter proteins and activating key pathways such as NF-κB and MAPK. This interaction promotes T cell–dependent B-cell activation, proliferation, antibody production, and immunoglobulin class switching.
Beyond B-cell regulation, CD40 signaling enhances the antigen-presenting capacity of dendritic cells and macrophages, promotes cytokine release, and contributes to immune modulation in inflammation, infection, and malignancy. In oncology, CD40/CD40L signaling is a promising therapeutic target. CD40 agonists enhance anti-tumor immunity, whereas blocking antibodies can downregulate autoimmune responses or prevent transplant rejection.
The measurement of B-cell CD40 expression by flow cytometry provides valuable information on immune competence, assists in identifying candidates for immunotherapy targeting this pathway, and supports precision-medicine approaches across immune, autoimmune, and oncologic disorders.
Genetic variants that disrupt CD40 expression lead to defective immunoglobulin class switching from IgM to IgG or IgA, resulting in hyper-IgM type 3 (HIGM3) syndrome. This rare autosomal recessive disorder (<1% of all HIGM syndromes) presents in infancy or early childhood with recurrent infections, low IgG/IgA, and markedly elevated IgM. Flow cytometry in affected patients shows an absence of CD40 expression on B-cells.
- As and aid in the diagnosis and monitoring of hyperimmunoglobulin M syndromes (hyper-IgM type 3, CD40 deficiency) syndrome
- Aid in the diagnosis of other immunodeficiencies (Common variable immunodeficiency)
- Aid in the diagnosis of lymphomas (diffuse large B-cell lymphoma, Burkitt lymphoma)
The assay qualitatively determines CD40 expression on B-cells.
Normal: Presence of CD40 expression on the majority of B-cells
Abnormal: Absence or markedly reduced CD40 expression, consistent with hyper-IgM type 3 syndrome
This is a screening test; molecular confirmation by CD40 gene sequencing is required for definitive diagnosis and identification of pathogenic variants.
Note: this assay differs from CD40L expression testing, which is used to diagnose X-linked hyper-IgM syndrome.
Present (Presence of CD40 on B-cell surface)
Flow cytometry.
Specimen: EDTA (Lavender-top) vial.
Stability
- Ambient: 72 hrs.
- Refrigerated: 3 days.
- Frozen: unacceptable
CD40 gene analysis (sequencing), serum immunoglobulins, serum IgM, CBC, lymphocyte subset analysis, lymph node biopsy.
3 to 4 days.
- Crit Rev Immunol. 2017;37(2-6):371-420. [PMID: 29773027]
- Oncotarget. 2017 Apr 25;8(17):27740-27753. [PMID: 26934557]
- Int Immunopharmacol. 2021 Feb;91:107337. [PMID: 33401206]
- Pharmacol Ther. 2021 Mar;219:107709. [PMID: 33091428]
- Immunobiology. 2020 Mar;225(2):151899. [PMID: 31899051]